MAIA 2021 029
Alternative Names: MAIA-2021-029Latest Information Update: 21 Jun 2023
At a glance
- Originator MAIA Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer